BridgeMD
A Phase 2b Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Graves' Disease
EU CTIS ID: 2025-521920-31-00
What this study is testing
To evaluate the efficacy of IMVT-1402 dose 1 versus placebo as assessed by T3 (Total T3 or FT3), FT4, TSH, and ATD dose at Week 26
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Participants with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures
- Male or female participants aged ≥ 18 years
- Participants with diagnosis of GD who are hyperthyroid despite ATD treatment
You likely can't join if
- Have previously been successfully treated with RAI therapy or have undergone total thyroidectomy.
- Have an autoimmune disease other than GD requiring treatment that, in the Investigator’s judgment, puts the participant at undue risk
- Have moderate-to-severe active thyroid eye disease (TED) and are expected to require immediate surgical intervention and/or are planning corrective surgery/irradiation or medical therapy for TED during study participation
The study team makes the final eligibility decision.
Where it's taking place
- Brazil
- Chile
- Israel
- Japan
- Georgia
- United Kingdom
- Korea, Republic of
- New Zealand
- Australia
- United States
- Mexico
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Brazil; Chile; Israel; Japan; Georgia; United Kingdom and 5 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.